Nalaganje...
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
AIMS: Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit...
Shranjeno v:
| izdano v: | ESC Heart Fail |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160493/ https://ncbi.nlm.nih.gov/pubmed/32022485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12627 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|